UNSPSC 51141588: Cabergoline diphosphate

This classification denotes a dopamine agonist and antiparkinsonian agent with the molecular formula C26H37N5O2.2H3O4P, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 477M7SA9N9, chemically known as ergoline-8-carboxamide, n-(3-(dimethylamino)propyl)-n-((ethylamino)carbonyl)-6-(2-propenyl)-, (8.beta.)-, phosphate (1:2), but more generally known as cabergoline diphosphate, which bears US NIH Compound Identifier 83879.

European Medicines Agency schedules cabergoline diphosphate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06041MIG. Most nations, for tariff purposes, schedule cabergoline diphosphate under HS 29396900. SMILES: CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@@H]2C3CCCC4C3C(C[NH]4)C[C@H]2N(C1)CC=C.OP(=O)(O)O.OP(=O)(O)O.

UNSPSC 51141588 Cabergoline diphosphate is a Commodity code that in practice captures state and local procurement of pharmaceutical products and systems supporting public health initiatives, though the recent solicitations tagged under this code show minimal direct connection to cabergoline itself. The three most recent opportunities reflect instead a broader demand pattern: Seminole County, Florida is sourcing naloxone and drug deactivation systems for community health delivery; Texas HHS is exploring direct-to-manufacturer prescription programs through an RFI; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is aggregating generic multi-source pharmaceuticals and OTC products across participating state and local governments. The issuing bodies include county health departments, state health and human services agencies, and cooperative purchasing organizations serving multiple jurisdictions, indicating that pharmaceutical procurement spans both individual localities and multi-state cooperative vehicles. Work solicited under this code encompasses product sourcing with compliance requirements for cGMP certification, Drug Supply Chain Security Act (DSCSA) adherence, FDA compliance, E-Verify and drug-free-workplace certification, insurance coverage (commercial general liability typically $5 million per occurrence), and quarterly or ongoing delivery logistics.

Geographic activity centers on the Southeast (Florida) and Upper Midwest (Minnesota, Oregon participating through MMCAP), with additional state-level activity in Texas. The Seminole County IFB for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually, quarterly delivery, response deadline July 26, 2023) represents direct county procurement with a two-year initial term and one-year renewal option. MMCAP's RFP for generic multi-source pharmaceuticals (response deadline March 26, 2026, contract effective July 1, 2026) reflects cooperative purchasing scale, with pricing weighted 75 percent and product competitiveness as the dominant evaluation factor; vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC) and accept a 3 percent administrative fee. The Texas HHS RFI (response deadline April 3, 2026) signals exploratory procurement, seeking vendor capabilities for direct-to-manufacturer prescription programs rather than immediate product sourcing. The code shows recent activity but with minimal direct cabergoline solicitation; opportunities are instead anchored in broader pharmaceutical supply, naloxone systems, and multi-jurisdiction cooperative contracting.